Literature DB >> 14596506

A systematic overview of radiation therapy effects in head and neck cancer.

Björn Zackrisson1, Claes Mercke, Hans Strander, Johan Wennerberg, Eva Cavallin-Ståhl.   

Abstract

UNLABELLED: A systematic review of radiation therapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for evaluation of the scientific literature are described separately (Acta Oncol 2003; 42: 357-365). This synthesis of the literature on radiation therapy for head and neck cancer is based on data from 39 randomized trials and 1 meta-analysis. In total, 40 scientific articles are included, involving 20893 patients. The results were compared with those of a similar overview from 1996 including 79 174 patients. The conclusions reached can be summarized as follows: General, non-nasopharynx. Substantial evidence indicates that the tumour effect of radiotherapy can be increased by the concomitant administration of chemotherapeutic agents, particularly cisplatin and 5-fluorouracil. There is moderate evidence of a survival benefit of radiation combined with concomitant chemotherapy compared to radiation alone. However, the results are equivocal. There is substantial evidence in published studies for an increased frequency of severe acute side effects as a result of concomitant chemotherapy and radiotherapy. There are very few studies that allow any estimates of the risk for serious late side effects. There is a weak indication of an increased risk for serious fibrosis. COMMENT: The general quality of studies and the lack of information on serious side effects indicate a need for large, well-designed clinical studies with a reasonable follow-up. Larynx preservation studies. There is strong evidence that larynx preservation is possible in 50% of the patients surviving for 5 years with hypopharyngeal cancers when treated with neoadjuvant chemotherapy and radical radiotherapy There is a non-significant trend for the overall survival being lower in non-surgically treated patients than in those treated with primary surgery and postoperative radiotherapy Nasopharynx. There is moderate evidence that patients with nasopharyngeal carcinomas of the endemic type benefit from therapy with a combination of chemotherapy and radical radiotherapy. However, the results from the reported studies are equivocal. There is some indication that the acute side effects of radiation are more severe in the concomitant setting than in the neoadjuvant. COMMENT: There are no data on serious late toxicity. Dose, fractionation schedules. There is some evidence that certain schedules of altered fractionation improve tumour control without increasing severe late side effects. There is some evidence that nervous tissues are more susceptible to damage by altered fractionation. Solid data shows that altered fractionation increases acute side effects. There is moderate evidence that accelerated hyperfractionation may reduce the frequency of serious late side effects while retaining a similar tumour effect as conventional radiotherapy Hypoxic cell sensitizers. Most reported trials reject the usefulness of nitroimidazole derivatives for sensitization of hypoxic tumour cells. There is some evidence that patients with tumours in the pharynx and larynx may benefit from sensitization by nimorazole. Prophylactic treatment of side effects. There is weak evidence that local antibiotics have a clinically significant effect in preventing acute radiotherapy side effects. There is insufficient evidence that radioprotective agents offer clinically significant protection of parotid glands (one study in two publications). There is insufficient evidence that radioprotective agents do not spare tumour tissue. Since the previous report no randomized studies comparing the effectiveness of external beam radiotherapy and brachytherapy have been performed. Both methods are well established and have independently proved to be effective in the treatment of certain head and neck cancers. No conclusion can be drawn regarding their relative effectiveness. Since the previous report no data to guide the use of intraoperative radiotherapy have been identified.

Entities:  

Mesh:

Year:  2003        PMID: 14596506     DOI: 10.1080/02841860310014886

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  20 in total

1.  Radiotherapy: Accelerated radiotherapy for HNSCC in developing countries.

Authors:  Bruce Brockstein; Everett E Vokes
Journal:  Nat Rev Clin Oncol       Date:  2010-11       Impact factor: 66.675

2.  Yet another function of p53--the switch that determines whether radiation-induced autophagy will be cytoprotective or nonprotective: implications for autophagy inhibition as a therapeutic strategy.

Authors:  Shweta Chakradeo; Khushboo Sharma; Aisha Alhaddad; Duaa Bakhshwin; Ngoc Le; Hisashi Harada; Wataru Nakajima; W Andrew Yeudall; Suzy V Torti; Frank M Torti; David A Gewirtz
Journal:  Mol Pharmacol       Date:  2015-02-09       Impact factor: 4.436

3.  Dendritic cell subpopulations in nasopharyngeal cancer.

Authors:  Johan S Nilsson; Milad Abolhalaj; Kristina Lundberg; Malin Lindstedt; Lennart Greiff
Journal:  Oncol Lett       Date:  2018-12-14       Impact factor: 2.967

Review 4.  Opportunities for rehabilitation of patients with radiation fibrosis syndrome.

Authors:  Katarzyna Hojan; Piotr Milecki
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-08

Review 5.  The effect of prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement on swallowing and swallow-related outcomes in patients undergoing radiotherapy for head and neck cancer: a systematic review.

Authors:  Stephanie M Shaw; Heather Flowers; Brian O'Sullivan; Andrew Hope; Louis W C Liu; Rosemary Martino
Journal:  Dysphagia       Date:  2015-03-04       Impact factor: 3.438

6.  Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer.

Authors:  Aline Lima da Silva Deboni; Adelmo José Giordani; Nilza Nelly Fontana Lopes; Rodrigo Souza Dias; Roberto Araujo Segreto; Siri Beier Jensen; Helena Regina Comodo Segreto
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

7.  Importance of patient, tumour and treatment related factors on quality of life in head and neck cancer patients after definitive treatment.

Authors:  Zumre Arican Alicikus; Fadime Akman; Ozlem Uruk Ataman; Nihal Dag; Esmahan Orcin; Betul Bakis; Munir Kinay
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-19       Impact factor: 2.503

8.  Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.

Authors:  Andrean L Simons; Melissa A Fath; David M Mattson; Brian J Smith; Susan A Walsh; Michael M Graham; Richard D Hichwa; John M Buatti; Ken Dornfeld; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

9.  Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study.

Authors:  Arlene Khaw; Sharon Liberali; Richard Logan; Dorothy Keefe; P Mark Bartold
Journal:  Support Care Cancer       Date:  2014-03-20       Impact factor: 3.603

10.  GTV delineation in supraglottic laryngeal carcinoma: interobserver agreement of CT versus CT-MR delineation.

Authors:  Elise Anne Jager; Nicolien Kasperts; Joana Caldas-Magalhaes; Mariëlle E P Philippens; Frank A Pameijer; Chris H J Terhaard; Cornelis P J Raaijmakers
Journal:  Radiat Oncol       Date:  2015-01-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.